Coral Laboratories Ltd vs Sanofi India Ltd Stock Comparison
Coral Laboratories Ltd vs Sanofi India Ltd Stock Comparison
Last Updated on: Jun 14, 2026
Key Highlights
The Latest Trading Price of Coral Laboratories Ltd is ₹ 489.8 as of 12 Jun 15:30
. The P/E Ratio of Coral Laboratories Ltd is 0 as of December 2023
.The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023
. The Market Cap of Coral Laboratories Ltd is ₹ 0 crore as of December 2023
.The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023
. The Revenue of Coral Laboratories Ltd is ₹ 0 crore as of Jun '24
.The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24
. The EBITDA of Coral Laboratories Ltd is ₹ 0 crore as of Jun '24
.The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24
. The Net Profit of Coral Laboratories Ltd is ₹ 0 crore as of Jun '24
.The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24
. The dividend payout of Coral Laboratories Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0%
The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00%
.
About Coral Laboratories Ltd
Coral Laboratories Limited (CLL) was established in February, 1997.
It was promoted by Navin B Doshi of the DWD Group.
To manufacture pharmaceutical formulations like tablets, capsules, liquid and topical preparation, the Company came up with a public issue in March, 1994 by raising funds of Rs.2.5 Crore.
It setup an additional ultra-modern manufacturing unit at Daman and the said Unit started the commercial production during March 2004.
It started the commercial production at Dehradun Plant in September, 2006.
Presently, Company is into manufacturing of Generic Branded, Nutraceuticals, OTC and Herbal Medicines.
About Sanofi India Ltd
Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.
FAQs for the comparison of Coral Laboratories Ltd and Sanofi India Ltd
Which company has a larger market capitalization, Coral Laboratories Ltd or Sanofi India Ltd?
Market cap of Coral Laboratories Ltd is 174 Cr while Market cap of Sanofi India Ltd is 8,111 Cr
What are the key factors driving the stock performance of Coral Laboratories Ltd and Sanofi India Ltd?
The stock performance of Coral Laboratories Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Coral Laboratories Ltd and Sanofi India Ltd?
As of June 14, 2026, the Coral Laboratories Ltd stock price is INR ₹489.8. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.
How do dividend payouts of Coral Laboratories Ltd and Sanofi India Ltd compare?
To compare the dividend payouts of Coral Laboratories Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.